小剂量螺内酯治疗高龄肺心病慢性心功能不全疗效及安全性研究  

Study on safety and efficacy of lower doses spironolactone in advanced age patients with the chronic heart failure of pulmonary heart disease

作　　者：黄红[1] 杨天睿[1] 全晶[1] 全胜麟[1] 杨燕[1] 石英[1] 

机构地区：[1]云南省第一人民医院内干科,云南昆明650032

出　　处：《中国医药科学》2013年第19期95-96,共2页China Medicine And Pharmacy

摘　　要：目的评价小剂量螺内酯治疗高龄肺心病慢性心功能不全疗效及安全性。方法选择56例高龄肺心病合并慢性心功能不全患者,随机分为治疗组(26例),对照组(30例),两组均给予常规治疗,治疗组给予螺内酯20mg,每日1次,平均服用半年。两组患者随访结束时检测肺动脉压及血浆B型脑钠肽前体(pro-BNP)反应疗效指标;检测血清钾、尿酸、肌酐、尿素氮水平及观察乳房发育、乳腺疼痛等副反应指标。结果治疗组肺动脉压及pro-BNP均较对照组降低,差异有统计学意义(P<0.01),而两组中血清钾、尿酸、肌酐、尿素氮比较差异无统计学意义(P>0.05),所有患者中均未发现有乳房发育、乳腺疼痛发生。结论小剂量螺内酯治疗高龄肺心病慢性心功能不全有效且安全。Objective To investigate the efficacy and safety of lower doses spironolactone in advanced age patients with the chronic heart failure of pulmonary heart disease. Methods Fifty six patients with the chronic heart failure of pulmonary heart disease were randomly divided into treatment group （n=26） and control group（n=30）. Both groups were given routine treatment and spironolactone was administered to patients 20mg bid in treatment group for about six months. Clinical effects were assessed by detecting pulmonary artery pressure, plasma pro-BNP. Safety were assessed by detecting the level of serum potassium, uric acid, creatinine, blood urea nitrogen and observing the chance of gynecomastia, breast pain. Results About pulmonary artery pressure and plasma pro-BNP, treatment group is obviously lower than control group （P 〈 0.01）, with statistical significance; Meanwhile, there were no significant differences in serum potassium, uric acid, creatinine, blood urea nitrogen level（P 〉 0.05）. All patients were not found gynecomastia and breast pain. Conclusion It is effective and safe for advanced age patients with the chronic heart failure of pulmonary heart disease in lower doses of spironolactone.

关 键 词：肺心病 慢性心功能不全 螺内酯 高龄 

分 类 号：R541.5[医药卫生—心血管疾病]